Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$27,000.00
Detangling placental and maternal origins of early- and late-onset preeclampsia
EF 2024-25
Résumé
Preeclampsia (PE) is a pregnancy complication in which maternal high blood pressure and organ damage develop after the 20th week of pregnancy. PE can be classified as early-onset PE, which develops before the 34th week of pregnancy, or late-onset PE, which develops at or after the 34th week of pregnancy. In addition to the short-term impacts of the disease, PE can have lasting effects on maternal and offspring health. The cause of preeclampsia remains poorly understood.
The placenta is an organ that forms during pregnancy and plays a critical role in fetal-maternal crosstalk for fetal health and growth. Abnormal placental development and function have been observed in PE. Cells normally release DNA fragments, called "cell-free DNA (cfDNA)" into blood circulation. During pregnancy, both the placenta and maternal blood cells release cfDNA into maternal blood circulation. Therefore, clinicians and researchers can access placental DNA for screening and research purposes through a simple, non-invasive maternal blood draw as early as the 10th week of pregnancy.
DNA methylation is a reversible modification made to DNA that controls cellular identity and function. Its dysregulation can result in disease. Changes in placental and maternal blood cell DNA methylation have been observed in PE.
In this study, we aim to use cell-free DNA to investigate placental and maternal origins of PE. Placental and maternal cell-free DNA will be isolated from maternal blood and separated from each other to investigate tissue-specific DNA methylation changes in pregnancies complicated by PE compared to healthy pregnancies. Through this research, we hope to provide insights into the causes of PE and identify non-invasive biomarkers that will permit earlier detection and treatment of PE.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
536577
Name
Yuen Natalie C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Detangling placental and maternal origins of early- and late-onset preeclampsia
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cell-Free Dna; Dna Methylation; Epigenetics; Non-Invasive Prenatal Testing; Placenta; Preeclampsia; Pregnancy; Women'S Health
Abstract
Preeclampsia (PE) is a pregnancy complication in which maternal high blood pressure and organ damage develop after the 20th week of pregnancy. PE can be classified as early-onset PE, which develops before the 34th week of pregnancy, or late-onset PE, which develops at or after the 34th week of pregnancy. In addition to the short-term impacts of the disease, PE can have lasting effects on maternal and offspring health. The cause of preeclampsia remains poorly understood.
The placenta is an organ that forms during pregnancy and plays a critical role in fetal-maternal crosstalk for fetal health and growth. Abnormal placental development and function have been observed in PE. Cells normally release DNA fragments, called "cell-free DNA (cfDNA)" into blood circulation. During pregnancy, both the placenta and maternal blood cells release cfDNA into maternal blood circulation. Therefore, clinicians and researchers can access placental DNA for screening and research purposes through a simple, non-invasive maternal blood draw as early as the 10th week of pregnancy.
DNA methylation is a reversible modification made to DNA that controls cellular identity and function. Its dysregulation can result in disease. Changes in placental and maternal blood cell DNA methylation have been observed in PE.
In this study, we aim to use cell-free DNA to investigate placental and maternal origins of PE. Placental and maternal cell-free DNA will be isolated from maternal blood and separated from each other to investigate tissue-specific DNA methylation changes in pregnancies complicated by PE compared to healthy pregnancies. Through this research, we hope to provide insights into the causes of PE and identify non-invasive biomarkers that will permit earlier detection and treatment of PE.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yuen, Natalie C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~